|
Jul 3
|
ACHV: Achieve’s Busy Day
|
|
Jun 30
|
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
|
|
Jun 27
|
Sector Update: Health Care Stocks Retreat Late Afternoon
|
|
Jun 27
|
Top Midday Decliners
|
|
Jun 27
|
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
|
|
Jun 26
|
Achieve Life Sciences Announces Proposed Underwritten Public Offering
|
|
Jun 26
|
Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
|
|
Jun 26
|
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
|
|
Mar 12
|
ACHV: 2Q:25 NDA Submission
|
|
Mar 12
|
Q4 2024 Achieve Life Sciences Inc Earnings Call
|
|
Mar 12
|
Achieve Life Sciences Inc (ACHV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
|
|
Mar 11
|
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
|
|
Feb 18
|
Here are Rogue Funds Updates on Achieve Life Sciences (ACHV)
|